Evidence map›Paper›PMID 41523570›Full record

ReviewCureus2025

Nanovesicular Drug Delivery Systems for Overcoming Antibiotic Resistance.

Gopalakrishna Pillai, Satish Jankie

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gopalakrishna PillaiDepartment of Pharmaceutical Sciences, South University School of Pharmacy, Savannah, USA.
Satish JankieSchool of Pharmacy, The University of the West Indies, Mt. Hope, TTO.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the early success of treating bacterial infections with antibiotics, resistance development has become a global problem. Treatment of organisms that have become resistant to common antibacterial agents is challenging and can cause severe and extended illness, longer hospital stays, and increased medical costs. Bacteria may develop antibiotic resistance by multiple biochemical pathways, including target-site gene mutations, decreased permeability, drug uptake or efflux mechanisms that remove the drug from the host cells, and alterations in metabolic pathways. Several strategies to overcome antibacterial resistance are under investigation, such as modifying existing antibiotics, targeting bacterial enzymes, cell-penetrating antibiotics, nanoparticle drug delivery systems, and encapsulating antibiotics and macrophage-targeted nanoparticles conjugated with specific ligands. Among all these approaches, the nano-sized drug delivery systems have become the subject of intense investigations because of their special benefits, including increased stability of the antibiotic, enhanced permeation through cell membranes, and delivery inside the cytoplasm, as well as improved biodistribution and pharmacokinetics. This review compiles data on liposomes and niosomes, promising nanovesicular drug delivery systems capable of targeting antibiotics to fight resistant microorganisms.

Indexed as

drug deliveryliposomesnanodrug delivery systemsnanovesiclesniosomessurfactant nanovesicular systemstargeted drug delivery systems

Identifiers

PMID41523570
PMCPMC12788974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.